The U.S. Food and Drug
Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C
virus (HCV) infection.
Sovaldi is the first drug
that has demonstrated safety and efficacy to treat certain types of HCV
infection without the need for co-administration of interferon.
On November 22, FDA had
approved Olysio (Simeprevir) for treatment of chronic HCV.
No comments:
Post a Comment